AUTOLOGOUS ACTIVATED MONOCYTES GIVEN I P FOR COLONIC CARCINOMATOSIS

自体激活单核细胞注射治疗结肠癌

• 批准号: 3896348
• 负责人: J W SMITH
• 金额: --
• 依托单位: DIVISION OF CANCER TREATMENT
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3896348
• 关键词: carcinoma; human subject; human therapy evaluation; interferons; interleukin 2; leukocyte activation /transformation; monocyte; neoplasm /cancer immunotherapy; neoplasm /cancer surgery; passive immunization

Human monocytes that have been isolated and purified from the peripheral blood have been demonstrated to be capable of killing tumor targets in vitro following activation to cytotoxicity by interferon-gamma. The purpose of this study is to determine if autologous activated monocytes can be used as an effective form of adoptive immunotherapy for colon cancer patients with disease spread to the peritoneal cavity. This protocol is based on a previous BRMP protocol which employed a similar study design; however, the patient population had undergone laparotomy and complete surgical excision of all macroscopic tumor. The patients in that protocol tolerated leukapheresis and infusions of activated monocytes along with interferon-gamma with tolerable toxicity. This study will enroll patients who have measurable macroscopic disease to determine whether adoptively transferred activated monocytes have cytocidal activity against established tumor. Because the disease is limited to the peritoneal cavity, the infused monocytes will have adequate contact with the tumor deposits, and questions of trafficking should not complicate the analysis of their efficacy. Although the protocol has been open to patient entry for the past year, no patients were enrolled on the protocol due to the existence of a competing protocol using intraperitoneally administered interleukin-2 plus LAK cells. Now that protocol has been closed, it is expected that patient accrual will be significant for this study over the next two years.

已经从人单核细胞中分离和纯化的人单核细胞， 已经证明外周血能够杀死 体外肿瘤靶点在细胞毒性活化后， 干扰素-γ 本研究的目的是确定， 自体活化的单核细胞可用作 过继免疫治疗结肠癌患者的疾病 扩散到腹膜腔。 该协议基于 采用类似研究设计的既往BRMP方案; 然而，患者群体经历了剖腹手术， 所有肉眼可见肿瘤的完全手术切除。 患者 在耐受性白细胞去除术和输注活化 单核细胞沿着干扰素-γ，具有可耐受的毒性。 本研究将招募具有可测量的肉眼可见 疾病以确定过继转移是否激活 单核细胞对已建立的肿瘤具有杀细胞活性。 由于该病局限于腹膜腔， 输注的单核细胞将与肿瘤充分接触 存款和贩运问题不应使 分析其功效。 尽管该方案过去一直对患者开放 2010年，由于 存在竞争性方案， 给予白细胞介素-2加LAK细胞。 现在协议规定 已关闭，预计患者增加将 这对未来两年的研究很重要。